Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series

• Lawrence Kasherman,
• Swati Garg,
• Nairi Tchrakian,
• Blaise Clarke,
• Katherine Karakasis,
• Raymond H. Kim,
• Tracy L. Stockley,
• Neesha Dhani,
• Amit M. Oza,
• Stephanie Lheureux

Affiliations

Lawrence Kasherman

Division of Medical Oncology & Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1Z5, Canada

Swati Garg

Division of Medical Oncology & Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1Z5, Canada

Nairi Tchrakian

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada

Blaise Clarke

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada

Katherine Karakasis

Division of Medical Oncology & Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1Z5, Canada

Raymond H. Kim

Division of Medical Oncology & Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1Z5, Canada; Familial Cancer Clinic, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada

Tracy L. Stockley

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada; Advanced Molecular Diagnostics Laboratory, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto ON

Neesha Dhani

Division of Medical Oncology & Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1Z5, Canada

Amit M. Oza

Division of Medical Oncology & Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1Z5, Canada

Stephanie Lheureux

Division of Medical Oncology & Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1Z5, Canada; Corresponding author at: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 700 University Avenue Room 7-811, Toronto, ON M5G 1Z5, Canada.